


diabetes

A JOURNAL OF THE
AMERICAN DIABETES
ASSOCIATION.

www.diabetes.org/diabetes



ABSTRACT BOOK

57th Annual Meeting and Scientific Sessions
Saturday, June 21 — Tuesday, June 24, 1997

Hynes Convention Center
Boston, Massachusetts

| | |
|---|---------|
| 1996-1997 Officers and Board of Directors | i |
| Past Officers | iv |
| Awards Banquet | v |
| Banting Medal for Scientific Achievement | vi |
| Outstanding Scientific Achievement Award | vii |
| Past National Achievement Award Recipients | viii |
| 1996-1997 Professional Section Council Chairs | x |
| 1996-1997 Research Awards and Grants | xi |
| 1996-1997 Scientific Sessions Meeting Committee | xiv |
| 1996-1997 Abstract Reviewers | xiv |
| General Information | xv |
| Satellite Program | xvii |
| Scientific Sessions Day-At-A-Glance | xix |
| Faculty Roster | xxii |
| Scientific Sessions Program—Saturday, June 21, 1997 | xxviii |
| Scientific Sessions Program—Sunday, June 22, 1997 | xxcviii |
| Scientific Sessions Program—Monday, June 23, 1997 | 1 |
| Scientific Sessions Program—Tuesday, June 24, 1997 | lxi |
| Maps of Meeting Sites | lxi |
| Commercial Exhibits | lxxvii |
| Duality of Interest Information | lxxvii |
| Abstracts—Presented and Published | 1A |
| Abstracts—Published Only | 289A |
| Subject Index | 393 |
| Author Index | 407 |



DIAEAZ 46 Supplement (1) 1A-434 (1997)
ISSN 0012-1797

RECT AVAILABLE COPY

Pramlintide, an Analog of Human Amylin Improves Glycemic Control in Patients with Type II Diabetes Requiring Insulin.

ROBERT THOMPSON*¹, LEEANNE PEARSON*¹, STEVEN SCHOENFELD*¹, ORVILLE KOLTERMAN*¹. *San Diego, CA*

The effects of 4 weeks of subcutaneous administration of pramlintide, (Pr) an analog of human amylin, on glycemic control in 203 patients with Type II diabetes mellitus requiring insulin were examined in a randomized, double-blind, placebo-controlled, parallel-group trial. Statistically significant reductions in serum fructosamine concentration were observed in the Pr 30 µg QID group (17.5 ± 4.9 µmol/L), the Pr 60 µg TID group (24.1 ± 4.9 µmol/L) and the Pr 60 µg QID group (22.6 ± 4.1 µmol/L) compared to placebo (PBO) (3.5 ± 3.8 µmol/L). There also were statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at Week 4 within the Pr 60 µg TID group (28%) and the Pr 60 µg QID group (31%) compared to PBO (10%). Consistent with the reduction in fructosamine, there were also statistically significant reductions in HbA_{1c} in the Pr 30 µg QID group ($0.53 \pm 0.07\%$), the Pr 60 µg TID group ($0.58 \pm 0.07\%$) and the Pr 60 µg QID group ($0.51 \pm 0.08\%$) compared to placebo ($0.27 \pm 0.08\%$). Based on RBC lifespan, and assuming stable glycemic control, these reductions in HbA_{1c} in the Pr groups should increase over the following 2-3 months. The reductions in fructosamine and HbA_{1c} were accompanied by a statistically significant reduction in fasting total and LDL cholesterol. In contrast to treatment with insulin alone, there were trends towards decreased body weight in the Pr 60 µg TID and 60 µg QID groups. Furthermore, the incidence of hypoglycemia was no greater in any Pr group than in placebo. In conclusion, measurement of similar changes in both serum fructosamine concentration and HbA_{1c} suggests that pramlintide therapy for 28 days improves glycemic control in patients with Type II diabetes mellitus requiring insulin.